Business Summary

Alchemia is a drug discovery and development company with an FDA approved drug, Fondaparinux, a generic version of the anticoagulant drug; a late stage oncology product pipeline derived from the HyACT® platform within its wholly owned subsidiary, Audeo Oncology, Inc. and a proprietary drug discovery platform, VAST®. HyACT is a platform technology that uses the non-toxic and naturally occurring carbohydrate, hyaluronic acid (HA) as a targeting vehicle for a range of approved anticancer therapeutics. The Company's main product candidate is HA-Irinotecan which is in a clinical trial for the treatment of metastatic colorectal cancer. HA-Irinotecan is also in a clinical trial for small cell lung cancer.

Data provided by Mergent, Inc.

Recent Company News MORE »

Powered by Interactive Data Managed Solutions

Recent / Upcoming DR Events MORE »

  • No DR Events are available.
Data provided by Thomson Reuters, Inc.
DR Symbol AEMAY
CUSIP 01374K101
DR Exchange OTC
DR ISIN US01374K1016
Ratio DR:ORD 1:10
Depositary BK (Sponsored)
Effective Date Nov 03, 2004
Underlying ISIN AU000000ACL6
Underlying SEDOL 6716408
Country Australia
Industry Pharma. & Biotech.

Powered by Interactive Data Managed Solutions

Monthly DR Trading Summary MORE »

Month Month End
DR Close
Price
DR Trading Volume Avg Day DR
Trading
Volume
Jul. 14 5.25 n/a n/a
Jun. 14 5.24 n/a n/a
May. 14 4.47 n/a n/a
Data provided by Interactive Data Corp.

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to
"Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE
Data provided by Thomson Reuters, Inc.

© 2014 The Bank of New York Mellon Corporation. Depositary Receipt business and services are conducted through The Bank of New York Mellon.

Quotes delayed at least 15 minutes.Market data provided by Interactive Data
Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.

Certain information included in this website is proprietary to Mergent, Inc. (Mergent) Copyright © 2003-2010. Reproduction of such information in any form is prohibited. Because of the possibility of
human or mechanical error by Mergent's sources, Mergent or others, Mergent does not guarantee the accuracy, adequacy, completeness, timeliness or availability or for the results obtained from the
use of such information. Mergent Terms of Use apply

Holdings information provided by FactSet Research Systems Inc. Copyright © 2003-2014 FactSet Research Systems Inc. All rights reserved.

Thomson Reuters Marks: The THOMSON REUTERS Kinesis Logo depicted below and THOMSON REUTERS

Redistributor shall display or print the Thomson Reuters Trademarks when Redistributor’s Customers are given access to the Services.

Where Redistributor makes available on display any and all Thomson Reuters Marks attributable to the Services, Redistributor shall include the following language in the Help About
section or in a general attribution page: “The THOMSON REUTERS Kinesis Logo and THOMSON REUTERS are trademarks of Thomson Reuters and its affiliated companies in the
United States and other countries and used herein under license.”

Additional Attribution Guidelines by Thomson Reuters: Redistributor shall display or print the following notice in the Help About section or in a general attribution page. “Copyright ©,
Thomson Reuters, 1999-2014. All Rights Reserved. Use, duplication, or sale of this service, or data contained herein, except as described in the [Authorized Products name]
Subscription Agreement, is strictly prohibited.”